Product Highlight - WELIREG
10 Dec 2025
- WELIREG (belzutifan) is indicated for adults with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.1
- Belzutifan inhibits hypoxia-inducible factor 2 alpha (HIF-2α), a transcription factor involved in oxygen sensing and regulation of genes that promote adaptation to hypoxia.1
- Lack of functional VHL protein stabilizes HIF-2α, which interacts with HIF-1β to induce tumor-related genes; belzutifan binds HIF-2α and blocks this interaction, reducing expression of target genes.1
Reference: 1. Welireg Full Prescribing Information April 2023.
Welireg is eligible for government funding in Hong Kong now!
This material is made available with the support from MSD (HK-BEL-00049 Nov/2025)
MERCK SHARP & DOHME (ASIA) LTD.
27/F, Lee Garden Two, 28 Yun Ping Rd, Causeway Bay
Tel: (+852) 3971 2800
Fax: (+852) 2834 0756
